| Alkaloid (11) |  |
| Allergan (6) | |
| Astrazeneca (7) | |
| Basi (302) | |
| Bayer (10) | |
| F hoffmann la roche ltd (24) | |
| Glaxosmithkline (15) | |
| Novartis (22) | |
| Pfizer (10) | |
| Sanofi (5) | |
| Alkaloid (11) | |
| Allergan (6) | |
| Astrazeneca (7) | |
| Basi (302) | |
| Bayer (10) | |
| F hoffmann la roche ltd (24) | |
| Glaxosmithkline (15) | |
| Novartis (22) | |
| Pfizer (10) | |
| Sanofi (5) | |
Last month, pharmaceutical giant Allergan bought the worldwide rights to that specific device called Liris (for lidocaine-releasing intravesical system), for $69 million up front and what could total more than $600 million in milestone payments.
Allergan is prepping for phase-three clinical trials for Liris, which can deliver 400 milligrams of lidocaine to patients.
Although future progress now depends on Allergan, Cima hopes to see Liris used commercially in a couple of years.
drew Allergan to invest in and eventually buy the technology. Taris tested the device on IC patients, many of
With the Allergan acquisition funds, Taris will further develop the device to deliver drugs for other bladder diseases,
included Yong Zhang, Phd (LIMR), Iossif Strehin, Phd (Allergan), and Phillip Messersmith, Phd (University of California, Berkeley)."
< Back - Next >
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011